Skip to main content
    M

    Moderna Inc (MRNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $198.85
    -1.25 (-0.62%)

    Market Cap: $79.39B

    Last updated: Oct 27, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(21/31)
    Avg Surprise
    -11.29%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.25
    Range$-3.28 - $-0.53
    15 analysts
    EPS Revisions
    2
    0
    7d
    3
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-1.22-2.0%
    60d ago$-1.35+7.5%
    30d ago$-1.29+3.1%
    7d ago$-1.27+1.7%
    Current$-1.25
    Revenue Consensus
    $892M
    Range$836M - $1.1B
    14 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.22
    Range$-3.39 - $0.52
    21 analysts
    Revenue Consensus
    $869M
    Range$731M - $922M
    21 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.22---
    Sep 26EST
    		-$-1.25---
    Jun 26
    Reported Jul 31
    		$-1.97$-1.97+0.00%Beat+7.5%
    Mar 26
    Reported May 1
    		$-3.40$-2.11-61.14%Miss-34.9%
    Dec 25
    Reported Feb 13
    		$-2.11$-2.64+20.08%Beat+27.5%
    Sep 25
    Reported Nov 6
    		$-0.51N/A+76.39%Beat-1800.0%
    Jun 25
    Reported Aug 1
    		$-2.13$-3.00+29.00%Beat+36.0%
    Mar 25
    Reported May 1
    		$-2.52$-3.11+18.97%Beat+17.9%
    Dec 24
    Reported Feb 14
    		$-2.91$-2.76-5.44%Miss-629.1%
    Sep 24
    Reported Nov 7
    		$0.03N/A+101.58%Beat+100.3%
    Jun 24
    Reported Aug 1
    		$-3.33$-3.35+0.60%Beat+8.0%
    Mar 24
    Reported May 2
    		$-3.07$-3.57+14.01%Beat-1715.8%
    Dec 23
    Reported Feb 22
    		$0.55$-0.97+156.70%Beat-84.8%
    Sep 23
    Reported Nov 2
    		$-9.53$-2.05-364.88%Miss-476.7%
    Jun 23
    Reported Aug 3
    		$-3.62$-4.12+12.14%Beat-169.1%
    Mar 23
    Reported May 4
    		$0.19N/A+110.73%Beat-97.8%
    Dec 22
    Reported Feb 23
    		$3.61$4.60-21.52%Miss-68.0%
    Sep 22
    Reported Nov 3
    		$2.53$3.11-18.65%Miss-67.1%
    Jun 22
    Reported Aug 3
    		$5.24$4.49+16.70%Beat-18.9%
    Mar 22
    Reported May 4
    		$8.58$5.62+52.67%Beat+202.1%
    Dec 21
    Reported Feb 24
    		$11.29$9.90+14.04%Beat+1736.2%
    Sep 21
    Reported Nov 4
    		$7.70$9.42-18.26%Miss+1405.1%
    Jun 21
    Reported Aug 5
    		$6.46$5.86+10.24%Beat+2183.9%
    Mar 21
    Reported May 6
    		$2.84$2.47+14.98%Beat+911.4%
    Dec 20
    Reported Feb 25
    		$-0.69$-0.35-97.14%Miss-86.5%
    Sep 20
    Reported Oct 29
    		$-0.59$-0.37-59.46%Miss-59.5%
    Jun 20
    Reported Aug 5
    		$-0.31$-0.36+13.89%Beat+24.4%
    Mar 20
    Reported May 7
    		$-0.35$-0.36+2.78%Beat+12.5%
    Dec 19
    Reported Feb 26
    		$-0.37$-0.42+11.90%Beat+79.2%
    Sep 19
    Reported Nov 6
    		$-0.37$-0.44+15.91%Beat+28.8%
    Jun 19
    Reported Aug 7
    		$-0.41$-0.45+8.89%Beat-41.4%
    Mar 19
    Reported May 9
    		$-0.40$-0.36-11.11%Miss-
    Dec 18
    Reported Mar 6
    		$-1.78$-0.36-394.44%Miss-
    Sep 18
    Reported Dec 7
    		$-0.52$0.00N/AMiss-
    Jun 18
    Reported Jun 30
    		$-0.29N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-24.89EV/EBITDAN/A
    Price/FCF-63.62xFCF Yield-1.57%
    Profitability
    Profit Margin-141.40%Operating Margin-558.00%
    ROE-39.00%ROIC-45.79%
    Financial Health
    Debt/Equity0.09xInterest CoverageN/A
    Current Ratio2.29xQuick Ratio2.18x
    Trading Statistics
    Beta1.09Avg Volume19.71M
    52-Week High$254.4852-Week Low$22.28

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$221.34
    SMA 20$210.56
    SMA 50$173.86
    SMA 200$82.99
    EMA 10$214.03
    EMA 20$207.13
    EMA 50$174.14
    EMA 200$100.02

    MACD

    Line: 12.84Signal: 17.68Hist: -4.83

    ADX

    ADX: 49.8+DI: 22.5-DI: 22.5

    Aroon & PSAR

    Aroon Up88.0
    Aroon DownN/A
    PSAR$251.56

    Bollinger Bands

    Upper Band$246.90
    Lower Band$174.22
    %B Position3452%(Upper)
    Band Width0.34

    RSI (14-Day)

    Neutral
    49.8

    Momentum Oscillators

    Stoch %K26.8
    Stoch %D48.7
    Williams %R-75.5
    ROC (10d)-7.0%
    Momentum-14.89
    CCI (20d)-65.9
    MFI (14d)56.1

    Volatility Measures

    ATR (14d)$21.33(10.7%)
    StdDev (20d)18.17
    Hist Vol107.9%(High)

    Volume Flow

    VWAP$194.77
    OBV480.2M
    AD Line334.7M
    CMF (20d)0.212

    Volume Metrics

    Avg Vol (20d)20.0M
    Vol Ratio0.8x
    VWMA (20d)$209.78

    Pivot Points

    R3$234.35
    R2$220.66
    R1$210.38
    Pivot Point$196.69
    S1$186.41
    S2$172.72
    S3$162.44

    Advanced Oscillators

    TSI19.24
    Ultimate Osc56.8
    KST328.11

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$145.00M$389.00M$678.00M$1.02B$142.00M$108.00M$966.00M$1.86B$241.00M$167.00M$2.81B$1.83B
    Cost of Revenue$93.00M$955.00M$452.00M$207.00M$119.00M$90.00M$739.00M$514.00M$115.00M$96.00M$929.00M$2.24B
    Gross Profit$52.00M$-566,000,000$226.00M$809.00M$23.00M$18.00M$227.00M$1.35B$126.00M$71.00M$1.88B$-410,000,000
    Operating Expenses$867.00M$822.00M$1.08B$1.07B$930.00M$1.07B$1.47B$1.42B$1.49B$1.34B$1.88B$1.60B
    R&D$651.00M$649.00M$775.00M$801.00M$700.00M$856.00M$1.12B$1.14B$1.22B$1.06B$1.41B$1.16B
    SG&A$216.00M$173.00M$308.00M$268.00M$230.00M$212.00M$351.00M$281.00M$268.00M$274.00M$470.00M$442.00M
    Operating Income$-815,000,000$-1,388,000,000$-857,000,000$-260,000,000$-907,000,000$-1,050,000,000$-1,246,000,000$-70,000,000$-1,363,000,000$-1,266,000,000$6.00M$-2,012,000,000
    Interest Income$67.00M$72.00M$70.00M$73.00M$81.00M$90.00M$91.00M$103.00M$111.00M$120.00M$103.00M$105.00M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-767,000,000$-1,334,000,000$-799,000,000$-187,000,000$-818,000,000$-964,000,000$-1,184,000,000$21.00M$-1,279,000,000$-1,165,000,000$70.00M$-1,958,000,000
    Income Tax Expense$15.00M$9.00M$27.00M$13.00M$7.00M$7.00M$-64,000,000$8.00M$0$10.00M$-147,000,000$1.67B
    Net Income$-782,000,000$-1,343,000,000$-826,000,000$-200,000,000$-825,000,000$-971,000,000$-1,120,000,000$13.00M$-1,279,000,000$-1,175,000,000$217.00M$-3,630,000,000
    EBITDA$-781,000,000$-1,358,000,000$-815,000,000$-225,000,000$-860,000,000$-1,034,000,000$-1,234,000,000$-51,000,000$-1,377,000,000$-1,276,000,000$149.00M$-1,826,000,000
    EBIT$-834,000,000$-1,406,000,000$-869,000,000$-260,000,000$-899,000,000$-1,054,000,000$-1,275,000,000$-82,000,000$-1,390,000,000$-1,285,000,000$-33,000,000$-2,063,000,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MRNA

    News

    AstraZeneca may start work on cancer vaccines, CEO says

    AstraZeneca is exploring the development of cancer vaccines, a decision announced by CEO Pascal Soriot at a recent oncology conference. The company...

    Investing.com•10/27/26•Somewhat-Bullish

    CF Bankshares (NASDAQ:CFBK) Issues Quarterly Earnings Results

    CF Bankshares (NASDAQ:CFBK) reported quarterly earnings per share of $0.91, matching analysts' consensus estimates. The company showed a 10.10% return on equity and a 15.10% net margin...

    MarketBeat•10/27/26•Somewhat-Bullish

    Moderna shares slip as William Blair cuts rating on valuation after rally

    Moderna Inc (NASDAQ:MRNA) shares fell in premarket trading after William Blair downgraded the biotechnology company to Market Perform from Outperform...

    Investing.com•10/27/26•Bearish

    Why Acadia Pharmaceuticals Fell Even As Profit Rose

    Acadia Pharmaceuticals' stock has fallen 24.9% year-to-date despite European Commission approval for DAYBUE in Rett syndrome and increased Q2 2026 profits. Investors are weighing the success of DAYBUE and NUPLAZID...

    Simply Wall Street•10/27/26•Neutral

    William Blair downgrades Moderna stock rating on valuation concerns

    William Blair has downgraded Moderna (NASDAQ: MRNA) from Outperform to Market Perform due to valuation concerns after a significant stock increase. The firm cited the stock's 545% year-to-date rise and 250% surge since...

    Investing.com•10/27/26•Bearish

    MRNA Valuation and Fair Value

    P/E
    -24.9x
    Forward P/E
    23.0x
    P/FCF
    -63.6x
    PEG
    0.0x
    P/B
    11.7x
    See GNG's fair value

    MRNA Profitability: Margins, ROIC and FCF

    Gross margin
    23.4%
    Operating margin
    -558.0%
    Net margin
    -141.4%
    ROIC
    -45.8%
    ROE
    -39.0%
    FCF yield
    -1.6%

    MRNA Competitors

    CompanyTicker
    Cigna CorpCI
    Boston Scientific CorpBSX
    Regeneron Pharmaceuticals IncREGN
    Takeda Pharmaceutical Co Ltd ADRTAK
    Elevance Health IncELV
    Cencora Inc.COR
    Sanofi ADRSNY
    Cardinal Health IncCAH

    Sector: Healthcare

    MRNA Analyst Ratings

    Consensus
    Hold
    Analysts
    23
    Strong Buy
    1
    Buy
    4
    Hold
    15
    Sell
    2
    Strong Sell
    1

    MRNA Bull Case vs Bear Case

    Bear case

    • MRNA has a -141.4% net profit margin.

    MRNA Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    22.4%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-1.25
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    3 up, 0 down

    Frequently Asked Questions About MRNA

    Does MRNA pay dividends?

    Moderna Inc (MRNA) does not currently pay a regular dividend.

    What is MRNA's market cap?

    Moderna Inc (MRNA) has a market capitalization of $79.39B with a current stock price of $198.85.

    Related stocks

    Sector: Healthcare

    All stocks starting with M

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In